Literature DB >> 10807955

Lack of a role for inducible nitric oxide synthase in an experimental model of nephrotic syndrome.

L M Walker1, S V Shah, P R Mayeux.   

Abstract

Puromycin aminonucleoside (PAN) administration in rats produces an experimental model of nephrotic syndrome characterized by glomerular epithelial cell injury and proteinuria. The purpose of this study was to examine the role of nitric oxide (NO) in this model of minimal change glomerular disease. Aminoguanidine (AG) was used to inhibit inducible nitric oxide synthase (iNOS). Sprague-Dawley rats were divided into Control (N = 9), PAN (N = 14), AG (N = 2), and PAN + AG (N = 12) treatment groups. Control animals received saline (i.v. ), PAN animals received PAN (75 mg/kg, i.v.), and PAN + AG animals received PAN plus AG (50 mg/kg, i.p., twice daily). AG animals received a saline injection (i.v.) on day 0 in the place of PAN and then AG on the same schedule as the PAN + AG group. Animals were kept in metabolic cages, and urinary protein excretion and nitrite (NO(2)(-)) excretion were measured daily. PAN administration increased urinary NO(2)(-) excretion by day 2, and levels remained elevated through day 7. AG prevented this PAN-induced increase in urinary NO(2)(-) excretion. Plasma nitrate (NO(3)(-)) and NO(2)(-) (NOx) concentrations were also increased in the PAN and PAN + AG groups. iNOS protein expression was not detected in either the glomeruli or the cortex at day 7. Proteinuria developed in PAN animals on day 4 and increased steadily through day 7. PAN + AG animals showed a pattern similar to that of the PAN group. These results indicated that in contrast to models of proliferative glomerulonephritis, NO formation during PAN-induced nephrotic syndrome is increased but does not participate in the development of glomerular injury as measured by proteinuria.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807955     DOI: 10.1016/s0006-2952(00)00308-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

1.  Protection against puromycin aminonucleoside-induced chronic renal disease in the Wistar-Furth rat.

Authors:  Aaron Erdely; Gary Freshour; Cheryl Smith; Kevin Engels; Jean L Olson; Chris Baylis
Journal:  Am J Physiol Renal Physiol       Date:  2004-03-23

2.  NOx (nitrite/nitrate) in patients with pediatric nephrotic syndrome.

Authors:  Hisashi Kawashima; Yasuyo Kashiwagi; Chiako Watanabe; Satoshi Sato; Shigeo Nishimata; Kouji Takekuma; Akinori Hoshika; Yasuo Watanabe
Journal:  Pediatr Nephrol       Date:  2007-02-08       Impact factor: 3.714

3.  Effect of clofibrate on fatty acid metabolism in the kidney of puromycin-induced nephrotic rats.

Authors:  Yoshikazu Muroya; Osamu Ito
Journal:  Clin Exp Nephrol       Date:  2016-03-07       Impact factor: 2.801

4.  Yi Qi Qing Re Gao formula ameliorates puromycin aminonucleoside-induced nephrosis by suppressing inflammation and apoptosis.

Authors:  Yumin Wen; Yongli Zhan; Huijie Liu; Tingting Zhao; Liping Yang; Haojun Zhang; Xi Dong; Ping Li
Journal:  BMC Complement Altern Med       Date:  2015-05-27       Impact factor: 3.659

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.